ActiveAtlas Opportunity Score 82/100
RFA-DK-27-121
NIH/NIDDK — Optimal Anti-Obesity Medication Strategies in Children and Adolescents Clinical Centers (RFA-DK-27-121)
Open NIH/NIDDK U01 clinical-trial opportunity for clinical centers to test optimal anti-obesity medication strategies in children and adolescents. Applications are due October 9, 2026 at 5:00 PM local time of the applicant organization. Atlas rates N9+ fit as high but conditional where objective remote assessment and vitals collection are protocol-relevant within an experienced pediatric obesity clinical-trial program.
FundingNIDDK intends to commit $3,000,000 in direct costs in FY2027 for up to three awards. Application budgets are limited to $1,000,000 in direct costs per year for up to five years, including up to one planning year.
DeadlineOctober 9, 2026 at 5:00 PM local time of the applicant organization.
Last verifiedOctober 5, 2026
Required next actionConfirm current Section III eligibility, institutional research capacity, required consortium participation, and all submission requirements in RFA-DK-27-121 before the October 9, 2026 deadline.
Broad Eligibility
Multiple domestic organization types are eligible, but Clinical Centers should demonstrate successful experience conducting clinical trials of obesity treatment in children and adolescents. Active SAM/UEI, Grants.gov, eRA Commons, and PD/PI ORCID requirements apply. Only one application per institution is allowed.
Atlas Analysis
Atlas Opportunity Score 91/100. This NIH/NIDDK U01 supports qualified U.S.-based clinical centers participating in a research consortium under RFA-DK-27-121. Applicants must meet the experience, protocol, leadership, and collaboration requirements in the current NOFO. Atlas should treat the funder's current announcement and submission instructions as controlling.
The National Institute of Diabetes and Digestive and Kidney Diseases (NIDDK), part of NIH, is accepting U01 clinical-trial applications under RFA-DK-27-121 for clinical centers that will test anti-obesity medication treatment strategies in children and adolescents with obesity.
Deadline: October 9, 2026 at 5:00 PM local time of the applicant organization. NIDDK intends to commit $3,000,000 in direct costs in FY2027 for up to three awards. Application budgets are limited to $1,000,000 in direct costs per year, and the maximum project period is five years, including up to one planning year. Cost sharing is not required.
Atlas fit: High but conditional. The funded work centers on therapeutic pediatric obesity clinical trials. A legitimate role for the Nonagon N9+ device and platform could include protocol-defined objective remote physical assessment, vitals or clinical-data capture, telehealth-enabled follow-up, and distributed monitoring where those functions materially support safety, outcomes, or implementation in primary-care, rural, or access-constrained settings. N9+ is not the medication intervention and should not be forced into a study without a scientific rationale.
Eligible organization types include higher education, nonprofits, small businesses and other for-profits, state and local governments, Tribal organizations, eligible federal agencies, independent school districts, housing authorities, and faith or community organizations. However, the NOFO specifically expects Clinical Centers to demonstrate successful experience conducting pediatric obesity-treatment clinical trials and appropriate multidisciplinary expertise. Dr. Miltie should therefore be treated as a potential technology or research partner unless all direct-applicant clinical-trial capabilities are independently verified.
Source verificationOfficial government source · files.simpler.grants.govAtlas last verified this record October 5, 2026. Always use the funder's current application materials, amendments and portal instructions as the controlling source.View source and application materials ↗
